| Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies R Stuver, GL Shah, NS Korde, LE Roeker, AR Mato, CL Batlevi, DJ Chung, ... Cancer Cell 40 (6), 590-591, 2022 | 83 | 2022 |
| Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: results from the comprehensive oncology measures for peripheral T‐cell lymphoma … RN Stuver, N Khan, M Schwartz, M Acosta, M Federico, C Gisselbrecht, ... American journal of hematology 94 (6), 641-649, 2019 | 31 | 2019 |
| TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy WT Johnson, N Ganesan, ZD Epstein-Peterson, AJ Moskowitz, RN Stuver, ... Blood Advances 7 (17), 5172-5186, 2023 | 7 | 2023 |
| Therapeutic advances in relapsed and refractory peripheral T-cell lymphoma R Stuver, AJ Moskowitz Cancers 15 (3), 589, 2023 | 6 | 2023 |
| Current Treatment of Peripheral T-cell Lymphoma. R Stuver, ZD Epstein-Peterson, WT Johnson, N Khan, N Lewis, ... Oncology (08909091) 36 (5), 2022 | 6 | 2022 |
| The Peripheral T-cell Lymphomas OA O'Connor, WS Kim, L Zinzani Wiley-Blackwell, 2021 | 5 | 2021 |
| Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T‐cell lymphoma R Stuver, SM Horwitz, RH Advani, JM Vose, HJ Lee, N Mehta‐Shah, ... British journal of haematology 202 (3), 525-529, 2023 | 4 | 2023 |
| PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort SH Desai, RW Merryman, H Shah, LD Pederson, SM Geyer, N Ganesan, ... Blood 142, 182, 2023 | 3 | 2023 |
| Advances in the treatment of mycoses fungoides and Sezary syndrome: A narrative update in skin-directed therapies and immune-based treatments R Stuver, S Geller Frontiers in Immunology 14, 1284045, 2023 | 3 | 2023 |
| Survivorship care plans: Reaching a benchmark and striving to achieve intent R Stuver, J Faig, M Cadorette, W Decaneas, I Kaplan, C VanDeWege, ... JCO Oncology Practice 16 (10), e1249-e1254, 2020 | 3 | 2020 |
| Quality assessment of tumor boards across an academic and community cancer network. DA Roberts, R Stuver, I Schillevoort, JA Zerillo Journal of Clinical Oncology 36 (30_suppl), 122-122, 2018 | 3 | 2018 |
| Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas R Stuver, ZD Epstein-Peterson, SM Horwitz Haematologica 108 (12), 3244, 2023 | 2 | 2023 |
| Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and … AS Falade, RA Redd, H Shah, K Baron, S Iyengar, SH Desai, SM Ansell, ... Blood 142, 3062, 2023 | 2 | 2023 |
| CNS relapse in T-cell lymphoma index: a risk score to predict central nervous system relapse in patients with T-cell lymphomas RS Bhansali, F Ellin, M Cao, T Relander, W Li, Q Long, N Ganesan, ... Blood 140 (Supplement 1), 1481-1484, 2022 | 2 | 2022 |
| Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: extended follow-up with evaluation of baseline metabolic … R Stuver, L Michaud, C Casulo, RH Advani, EL Budde, PM Barr, ... Blood 140 (Supplement 1), 1756-1758, 2022 | 2 | 2022 |
| Emapalumab for Malignancy-Associated Hemophagocytic Lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center Experience WT Johnson, ZD Epstein-Peterson, N Ganesan, T Chang, N Galasso, ... Blood 140 (Supplement 1), 3704-3706, 2022 | 2 | 2022 |
| First report of bilateral breast-implant associated anaplastic large cell lymphoma caused by identical T-cell clone R Stuver, NE Lewis, MD Ewalt, A Dogan, BH Durham, G Plitas, ... Leukemia & Lymphoma 63 (11), 2747-2750, 2022 | 2 | 2022 |
| Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis N Shafagati, MJ Koh, L Boussi, HJ Park, R Stuver, P Bain, FM Foss, ... Blood Advances 6 (16), 4740-4762, 2022 | 2 | 2022 |
| A multi-institutional retrospective analysis of T-cell lymphomas with central nervous system relapse RS Bhansali, N Ganesan, RN Stuver, SM Horwitz, K Wudhikarn, ... Blood 138, 1382, 2021 | 2 | 2021 |
| Role of single agent and combination chemotherapy strategies in relapsed/refractory peripheral T-cell lymphoma: results from the complete registry R Stuver, N Khan, M Schwartz, M Acosta, M Federico, C Gisselbrecht, ... Blood 132, 2926, 2018 | 2 | 2018 |
Steven HorwitzMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
